Baicalein monohydrate | CAS# 352000-07-8 | 12-lipoxygenase inhibitor

MedKoo Cat#: 574575 | Name: Baicalein monohydrate

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Baicalein monohydrate is an inhibitor of 12-lipoxygenase, leukotriene biosynthesis and release of lysosomal enzymes. It also inhibits cellular Ca2+ uptake and mobilization and adjuvant-induced arthritis.

Chemical Structure

Baicalein monohydrate

CAS#352000-07-8 (hydrate)

Theoretical Analysis

MedKoo Cat#: 574575

Name: Baicalein monohydrate

CAS#: 352000-07-8 (hydrate)

Chemical Formula: C15H12O6

Exact Mass: 288.0634

Molecular Weight: 288.25

Elemental Analysis: C, 62.50; H, 4.20; O, 33.30

Price and Availability

Size	Price	Availability
1g	USD 250.00	2 Weeks
5g	USD 550.00	2 Weeks
10g	USD 750.00	2 Weeks
25g	USD 1,250.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

352000-07-8 (hydrate) 491-67-8

Synonym

Baicalein monohydrate

IUPAC/Chemical Name

5,6,7-Trihydroxyflavone Monohydrate

InChi Key

NPXBMGZSFXMEQA-UHFFFAOYSA-N

InChi Code

InChI=1S/C15H10O5.H2O/c16-9-6-11(8-4-2-1-3-5-8)20-12-7-10(17)14(18)15(19)13(9)12;/h1-7,17-19H;1H2

SMILES Code

O=C1C=C(C2=CC=CC=C2)OC3=C1C(O)=C(O)C(O)=C3.[H]O[H]

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

Baicalein is a xanthine oxidase inhibitor with an IC50 of 3.12 μM.

In vitro activity:

To measure the effect of baicalein on the proliferation of MCF-7 and MDA-MB-231 cells that were exposed to 0, 10, 20, and 40 µM of baicalein for 24, 48, and 72 hours, MTT assay was implemented. The results showed that baicalein significantly inhibited the proliferation of MCF-7 and MDA-MB-231 cells in a dose- and time-dependent manner (P<0.05, P<0.01, Figure 1B). Baicalein also suppressed the colony formation of MCF-7 and MDA-MB-231 cells as shown by the plate colony formation assay. As shown in Figure 1C, the numbers of colonies that formed for preparations treated with baicalein at 10, 20, and 40 µM were 118±2.6, 63±6.2, 25±3.7 and 85±1.6, 51±6.7, 19±3.6 in MCF-7 and MDA-MB-231 cells respectively (P<0.05). These results suggest that baicalein has anti-proliferative effects on breast cancer cells. Reference: Drug Des Devel Ther. 2018 Nov 16;12:3961-3972. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6248272/

In vivo activity:

The anticancer potential of baicalein was evaluated using breast xenografts models (BALB/c-nude) as the testing model. After therapeutic treatment with baicalein, tumor tissues from breast xenograft models were collected and analyzed. The results demonstrated that the growth, volume, and weight of tumors were significantly suppressed in the baicalein-treated group compared with the control group (Figure 5A–C, P<0.05). Additionally, the anti-tumor efficacy of baicalein in vivo was assessed by immunohistochemistry staining methods. As presented in Figure 5D, baicalein remarkably reduced the expression of p-AKT, while increasing the expression of Bax and LC3 at the protein level. These results illustrated that baicalein can significantly induce apoptosis and autophagy through negative modulation of the PI3K/AKT pathway in vivo. Reference: Drug Des Devel Ther. 2018 Nov 16;12:3961-3972. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6248272/

	Solvent	mg/mL	mM
Solubility
	DMF	52.0	192.42
	DMSO	48.9	180.88
	Ethanol	1.2	4.26

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 288.25 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Yan W, Ma X, Zhao X, Zhang S. Baicalein induces apoptosis and autophagy of breast cancer cells via inhibiting PI3K/AKT pathway in vivo and vitro. Drug Des Devel Ther. 2018 Nov 16;12:3961-3972. doi: 10.2147/DDDT.S181939. PMID: 30510404; PMCID: PMC6248272. 2. Guo J, You H, Li D. Baicalein Exerts Anticancer Effect in Nasopharyngeal Carcinoma In Vitro and In Vivo. Oncol Res. 2019 May 7;27(5):601-611. doi: 10.3727/096504018X15399945637736. PMID: 31053182; PMCID: PMC7848276.

In vitro protocol:

In vivo protocol:

1. Rubab K, Abbasi MA, Rehman A, et al. Synthesis, pharmacological screening and computational analysis of some 2-(1H-Indol-3-yl)-N'-[(un)substituted phenylmethylidene] acetohydrazides and 2-(1H-Indol-3-yl)-N'-[(un)substituted benzoyl/2-thienylcarbonyl]acetohydrazides. Pak J Pharm Sci. 2017;30(4):1263-1274.